多发性肺肿瘤患者中区分多原发腺癌与肺内转移的联合组织分子算法提案
研究连续纳入120例接受根治性手术的肺腺癌患者共240个肿瘤,采用WHO 2015组织学分类和22个热点基因二代测序进行分子分型,比较单独与联合分类的一致性。基因组与组织学分类κ=0.43,不一致的30/109对(27%)经联合组织分子算法重新分类。EGFR突变和淋巴结受累与肺内转移显著相关,KRAS突变与多原发肺腺癌显著相关。
要点
- 联合组织分子算法可对组织学与分子分型不一致的多发肺肿瘤进行重新分类。
- EGFR突变(p=0.03)和淋巴结受累(p=0.03)与肺内转移显著相关。
- KRAS突变(p=0.00005)与多原发肺腺癌显著相关,EGFR突变和淋巴结受累为独立预后因素。
核心结论
- 联合组织分子算法是区分多灶性肺癌的相关工具,可能指导辅助治疗决策。
- 生存分析强调肺内转移患者中EGFR突变腺癌预后良好。
研究设计与样本
- 研究连续纳入接受根治性手术的肺腺癌患者120例,共240个肿瘤。
- 采用WHO 2015分类进行组织学诊断,并用靶向22个热点基因的二代测序进行分子分型。
- 将样本分类为多原发肺腺癌或肺内转移,并比较组织学与分子分类的一致性。
主要发现
- 二代测序在91%的肿瘤对(109/120)中检出分子突变。
- 基因组与组织学分类的κ检验一致性为κ=0.43。
- 不一致病例为30/109(27%),经联合组织分子算法重新分类。
- EGFR突变(p=0.03)和淋巴结受累(p=0.03)与肺内转移显著相关。
- KRAS突变(p=0.00005)与多原发肺腺癌显著相关;EGFR突变(p=0.02)和淋巴结受累(p=0.004)是仅有的独立预后因素。
关键数值与推荐
- 联合组织分子算法用于对组织学与分子分型不一致的病例(30/109,27%)进行重新分类。
- EGFR突变(p=0.03)和淋巴结受累(p=0.03)与肺内转移显著相关。
- KRAS突变(p=0.00005)与多原发肺腺癌显著相关。
- EGFR突变(p=0.02)和淋巴结受累(p=0.004)是独立预后因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Multiple nodules in the lung are being diagnosed with an increasing frequency thanks to high-quality computed tomography imaging. In patients with lung cancer, this situation represents up to 10% of patients who have an operation. For clinical management, it is important to classify the disease as intrapulmonary metastasis or multiple primary lung carcinoma to define TNM classification and optimize therapeutic options. In the present study, we evaluated the respective and combined input of histological and molecular classification to propose a classification algorithm for multiple nodules. METHODS: We studied consecutive patients undergoing an operation with curative intent for lung adenocarcinoma (N = 120) and harboring two tumors (N = 240). Histological diagnosis according to the WHO 2015 classification and molecular profiling using next-generation sequencing targeting 22 hotspot genes allowed classification of samples as multiple primary lung adenocarcinomas or as intrapulmonary metastasis. RESULTS: Next-generation sequencing identified molecular mutations in 91% of tumor pairs (109 of 120). Genomic and histological classification showed a fair agreement when the κ test was used (κ = 0.43). Discordant cases (30 of 109 [27%]) were reclassified by using a combined histomolecular algorithm. EGFR mutations (p = 0.03) and node involvement (p = 0.03) were significantly associated with intrapulmonary metastasis, whereas KRAS mutations (p = 0.00005) were significantly associated with multiple primary lung adenocarcinomas. EGFR mutations (p = 0.02) and node involvement (p = 0.004) were the only independent prognostic factors. CONCLUSION: We showed that combined histomolecular algorithm represents a relevant tool to classify multifocal lung cancers, which could guide adjuvant treatment decisions. Survival analysis underlined the good prognosis of EGFR-mutated adenocarcinoma in patients with intrapulmonary metastasis.
引用
- Mansuet-Lupo A, Barritault M, Alifano M, et al. Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. J Thorac Oncol. 2019. PMID: 30721797. doi:10.1016/j.jtho.2019.01.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。